Testosterone Replacement Therapy On Male Late-Onset Hypogonadism With The Mild-To-Moderate Benige Prostate Hyperplasia

Objectives:To explore the safety and efficacy of testosterone replacement therapy in patients with male late-onset hypogonadism and Mild-to-moderate benige prostate hyperplasia.Methods:43 patients diagnosed as male late-onset hypogonadism and Mild-to-moderate benige prostate hyperplasia were selected,22 of them were assigned to Eleven acid testosterone (40 mg each time,2 times per day), other patients were in the control group. The patients were followed for a median of 12 months and their data about digital rectal inspection, size of the prostate, IPSS score, maximum urinary flow rate (Qmax), AMS clinical symptom score, serum testosterone level, serum PSA level, RBC hematocrit (HCT), and other indicators were collected.Results:After 12 months testosterone replacement therapy,both the prostate volume of treated and control groups were not significantly changed (P>0.05). IPSS score and maximum urinary flow rate in treatment group were improved significantly(P< 0.05), but the control group showed no statistically significant changes (P>0.05). Baseline AMS clinical symptom score and blood testosterone level were similar between treatment and control group (p>0.05). After 12 months treatment, the blood testosterone level of the treatment group reached the normal range, and the AMS clinical symptom scores decreased significantly (P< 0.05), However, none indexes of control group significantly changed after the treatment (P> 0.05).Conclusion:Testosterone replacement therapy in patients with male late-onset hypogonadism and the Mild-to-moderate benige prostate hyperplasia is safe and effective.